Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Suprasplicesome meeting, Amsterdam, 23 September 2019

Presentation by Elisa Giovannetti: “Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma”

The results of this study have been published in EBiomedicine:
www.ebiomedicine.com/article/S2352-3964(18)30602-9
Article PDF: Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Presentation PDF: Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Proteomic profiling of gemcitabine-resistant pancrea4c cancer cells unravels microtubule-associated protein 2 overexpression, that correlated to poorer survival but also to increased sensi4vity to nab-paclitaxel

Proteomic profiling of gemcitabine-resistant pancrea4c cancer cells unravels microtubule-associated protein 2 overexpression, that correlated to poorer survival but also to increased sensi4vity to nab-paclitaxel

AISP 2019, Verona 21 September 2019

Presentation by Mjriam Capula, who was awarded for the Best Oral Presentation in preclinical/translational research

Some results of this study have been published in Therapeutic Advances in Medical Oncology:
www.ncbi.nlm.nih.gov/pmc/articles/10.1177_1758835919841233.pdf

PDF file: Mjriam Capula – Presentazione AISP 2019

Cena AISP 2019

Cena AISP 2019

Testimonianza

Testimonianza

“Testimonianza” at Course organized by the association “Women for Oncology” of the Italian and European Association of Medical Oncology (Host: Dr. L. Locati, Dr. M. Garassino), Montecitorio, Roma, Italy 18 June 2019

Other information on the Italian association “Women for Oncology” are at: facebook.com/women4onco

PDF file: Testimonianza Giovannetti W40 2019

Tavola Rotonda Women for Oncology 2019

Tavola Rotonda Women for Oncology 2019

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells

In this video we discuss how pancreatic stellate cells (PSCs) represent a key component of tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and contribute to drug resistance. Moreober we explain that c-MET receptor tyrosine kinase activation plays an important role in tumorigenesis in different cancers including PDAC. Effects of PSC conditioned medium (PCM) on c-MET phosphorylation (by immunocytochemistry enzyme-linked immunosorbent assay (ELISA)) and drug response (by sulforhodamine B assay) were investigated in five primary PDAC cells. In novel 3D-spheroid co-cultures of cyan fluorescence protein (CFP)-firefly luciferase (Fluc)-expressing primary human PDAC cells and green fluorescence protein (GFP)-expressing immortalized PSCs, PDAC cell growth and chemosensitivity were examined by luciferase assay, while spheroids’ architecture was evaluated by confocal microscopy. PCM of cells pre-incubated with PDAC conditioned medium, containing increased hepatocyte growth factor (HGF) levels, made PDAC cells significantly more resistant to gemcitabine, but not to c-MET inhibitors. Hetero-spheroids containing both PSCs and PDAC cells were more resistant to gemcitabine compared to homo-spheroids. However, c-MET inhibitors (tivantinib, PHA-665752 and crizotinib) were equally effective in both spheroid models. In conclusion, we developed spheroid models to evaluate PSC-PDAC reciprocal interaction, unraveling c-MET inhibition as an important therapeutic option against drug resistant PDAC.

This video has been published as supplemental file to the article:

Cancers (Basel). 2019 May 8;11(5). pii: E638. doi: 10.3390/cancers11050638
Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E.
Link: www.ncbi.nlm.nih.gov/pubmed/31072019

Of note, the author of this paper, Professor Omidreza Firuzi (from the Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences , Shiraz, Iran), won the NWO Visitor’s Travel grant to work for one year in our lab.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

EORTC-PAMM Winter Meeting, Verona, Italy, 8th February 2019

Selected Oral presentation: “Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line”
By Dr. Alessandro Leonetti

The results of this study have been published in Biochemical Pharmacology:
www.ncbi.nlm.nih.gov/pubmed/31078602

PDF file: Decrease in p-PRAS40 plays a role in the synergy between erlotinib and crizotinib

Neighborhood matters: new tools and practical approaches for co-culturing cancer cells

Neighborhood matters: new tools and practical approaches for co-culturing cancer cells

Winter Meeting of the EORTC-PAMM 2019, Verona, Italy, 8th February 2019

Invited lecture at the Educational Course organized by the EORTC-PAMM group “Neighborhood matters: new tools and practical approaches for co-culturing cancer cells”

The discussion among students attending the course were published in the following articles in Anticancer Research:

  • A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”: www.ncbi.nlm.nih.gov/pubmed/31262863
  • To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology: www.ncbi.nlm.nih.gov/pubmed/31262850
  • Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology: www.ncbi.nlm.nih.gov/pubmed/31262864

PDF file: Neighborhood matters

Role of pharmacology in anticancer treatments

Role of pharmacology in anticancer treatments

Symposium “Pharmacology forever”
Amsterdam, The Netherlands, 20th April 2018

Invited lecture “Role of pharmacology in anticancer treatments” by Elisa Giovannetti

PDF file: Role of pharmacology in anticancer treatments

Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy

Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy

Winter Meeting of the EORTC-PAMM 2018, Roma, Italy, 7-10 February 2018

Oral presentation by Dr. Carmelo Tibaldi: Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.
Tibaldi C, Camerini A, Tiseo M,  Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Honeywell R, Chartoire M,  Peters GJ, Giovannetti E.

The results of this study have been published in British Journal of Cancer:
www.ncbi.nlm.nih.gov/pubmed/30405211

Moreover we wrote a commentary on CDA activity in British Journal of Clinical Pharmacology:
www.bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13921

PDF file: Prospective study on the role of cytidine deaminase activity

Optimizing immunotherapy: Rationale for a combination therapy approach

Optimizing immunotherapy: Rationale for a combination therapy approach

ESMO 2017: ESMO COLLOQUIUM

Optimizing immunotherapy: Rationale for a combination therapy approach
Invited Oral Presentation at the annual meeting of the European Society of Medical Oncology (ESMO) Congress, Madrid, September 2017

A review focusing on some of these studies has been published in Drug Resistance Updates: Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Link: www.sciencedirect.com/science/article/pii/S1368764619300330

PDF file: ESMO 2017

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing

European Pancreatic Club (EPC) Congress, Budapest, June 2017

The results of this study have been published in Scientific Reports:
www.nature.com/articles/srep44686

Pdf: Development of bioluminescent chick chorioallantoic membrane (CAM) models

Photo group EPC Congress Budapest 2017

Photo with our collaborators, including Dr. Le Large and Dr. Meijer (VUmc, Amsterdam), Dr. Frampton and Dr. Mato Prado (Imperial College London)